<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130634</url>
  </required_header>
  <id_info>
    <org_study_id>KMUHIRB-F(II)-20160038</org_study_id>
    <nct_id>NCT03130634</nct_id>
  </id_info>
  <brief_title>The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives: Use both listed and relatively safe drug, Silymarin,s to improve the
      intestinal side effect of the patients undergoing FOLFIRI chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      Use both listed and relatively safe drug, Silymarin, to improve the intestinal side effect of
      the patients undergoing FOLFIRI chemotherapy.

      Patient Selection and Enrollment:

      Number of Subjects: Eligible patients will be randomized in 2 arms in the ratio of 1:1, to
      reach approximately 50 patients in total.

      Plan of the Study:

      Study Design This is an open-label, randomized, comparative, double arm, single center study
      to assess efficacy of Silymarin as adjuvant therapy on metastatic colorectal cancer patients
      undergoing FOLFIRI chemotherapy in Taiwan.

      Subject Number Eligible patients will be randomized in 2 arms in the ratio of 1:1, to reach
      approximately 50 patients in total.

      Study Schedule Study date: the time getting approval letter issued by both regulatory
      authority and institutional review board (IRB) Duration of study: From the date of the IRB
      was approved till the 50th patient was collected.

      Duration of Enrollment: From the date of the IRB was approved till the 50th patient was
      collected.

      Duration of treatment: From the 1st patient starting chemotherapy till the 50th patient
      finishing the 6th cycle chemotherapy.

      Duration of follow-up: From the 1st patient starting chemotherapy till 3 months after the
      50th patient finishing the 6th cycle chemotherapy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GI associated adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Response rate and grades of GI associated adverse events (AEs) according to the Response Evaluation Criteria in Solid Tumors (version 1.1)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>prescription of silymarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>During six cycles of FOLFIRI chemotherapy, the patients will not take silymarin during chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.</description>
    <arm_group_label>prescription of silymarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient who is between 20 to 80 years old

          2. The patient who is diagnosed metastatic colorectal cancer and received chemotherapy
             with FOLFIRI regimen

          3. The female patient should not be pregnant or breast-feeding

          4. The patient who has no severe co-morbidity, such as cardiovascular, cerebrovascular,
             malignant hypertension, renal and hepatobiliary disease.

          5. The patient who has no associated drug allergy to this trial.

          6. The patient who is in compliance with prescribed medication.

          7. The patient who is willing to sign the permit of the clinical trial.

        Exclusion Criteria:

          1. The patients who do not meet the main inclusion criteria or are not willing to sign
             the permit.

          2. The patient who has viral hepatitis or carrier with impaired liver function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chung-Ho Memorial Hospital, Kaohsiung Medical University:</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaw-Yuan Wang, PhD</last_name>
      <email>cy614112@ms14.hinet.net</email>
    </contact>
    <contact_backup>
      <last_name>Tsung-Kun Chang, MD</last_name>
      <email>tsungkunchang@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jaw-Yuan Wang, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tsung-Kun Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2017</study_first_submitted>
  <study_first_submitted_qc>April 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Medical University Chung-Ho Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Jaw-Yuan Wang, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CPT-11(irinotecan)</keyword>
  <keyword>silymarin</keyword>
  <keyword>GI toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

